FDA Seeks Fines for Unauthorized Tobacco Sales from Retailers

Sep.24.2024

FDA seeks fines from 11 retailers for unauthorized tobacco sales, warning letters ignored, total penalty $20,678 each.

On September 23, the US Food and Drug Administration (FDA) announced that it is seeking fines against two physical retail establishments and nine online retailers. The FDA had previously issued warning letters to these retailers for selling unauthorized tobacco products, but follow-up inspections found that they had not corrected their violations. Therefore, the FDA is now seeking civil fines of $20,678 from each retailer.

So far, the FDA has filed civil penalty lawsuits against 70 manufacturers and 160 retailers, accusing them of distributing or selling unauthorized tobacco products.

References:

[1] FDA Seeks Civil Money Penalties Against 11 Retailers Selling Unauthorized E-Cigarettes

Also Read:

[1] Advancing Smoking Cessation: FDA and NIH Priorities

[2] US House Committee Questions FDA's Focus on E-cigarette Regulation

[3] U.S. FDA Youth Survey: ELFBAR Usage Drops to 36% After FDA Enforcement, ZYN Becomes Top Choice Among Teens

[4] FDA Proposed Rule Requires Importers to Submit STN for ENDS

[5] Study on the Impact of Public Health Communication on Tobacco

[6] U.S. Appeals Court Overturns FDA's E-cigarette Marketing Denial Order

#Law enforcement #North America #United States #Traditional tobacco

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com